Cullinan Therapeutics Inc
NASDAQ:CGEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cullinan Therapeutics Inc
NASDAQ:CGEM
|
US |
|
A
|
Abercrombie & Fitch Co
DUS:AFT
|
US |
|
T
|
Tyler Technologies Inc
F:TYP
|
US |
|
G
|
Gap Inc
XMUN:GAP
|
US |
|
Dynamatic Technologies Ltd
NSE:DYNAMATECH
|
IN |
|
C
|
Chorus Ltd
XMUN:7CH
|
NZ |
|
Z
|
Zhejiang Expressway Co Ltd
XMUN:ZHJ
|
CN |
|
C
|
Celsius Resources Ltd
F:FX8
|
AU |
Intrinsic Value
Is CGEM undervalued or overvalued?
See the intrinsic value estimate for Cullinan Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
CGEM looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with CGEM’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Cullinan Therapeutics Does
Cullinan Oncology is a biotech company that develops cancer drugs, especially therapies that aim to attack tumors more precisely while limiting harm to healthy tissue. It does not run a broad drug-selling business yet; instead, it advances a pipeline of experimental medicines through research, clinical testing, and partnerships with larger drugmakers.
- Headquarters
- United States of America US
- Employees
- 109
- IPO date
- Jan 8, 2021
Earnings Waterfall
Cullinan Therapeutics Inc
The intrinsic value for Cullinan Therapeutics Inc (CGEM) under the Base Case is hidden USD.
Compared with the current market price of 14.46 USD, the stock appears hidden.